News
- 2025/06/12
- Nippon Kayaku announces IBTROZITM approved in the U.S. for patients with advanced ROS1-positive Non-Small Cell Lung Cancer
- 2025/06/02
- Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced ROS1-positive Non-Small Lung Cancer at ASCO 2025
- 2025/05/30
- Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
- 2025/05/08
- Nippon Kayaku received MSCI ESG Ratings of AA for the second year
- 2025/03/03
- Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced ROS1-positive Non-Small Cell Lung Cancer in Japan
- 2025/01/07
- Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
